nodes	percent_of_prediction	percent_of_DWPC	metapath
Cinnarizine—CYP2A6—Nevirapine—acquired immunodeficiency syndrome	0.0735	0.0794	CbGbCtD
Cinnarizine—CYP2B6—Efavirenz—acquired immunodeficiency syndrome	0.0509	0.055	CbGbCtD
Cinnarizine—CYP2A6—Zidovudine—acquired immunodeficiency syndrome	0.0483	0.0522	CbGbCtD
Cinnarizine—CYP2B6—Lopinavir—acquired immunodeficiency syndrome	0.0479	0.0517	CbGbCtD
Cinnarizine—CYP2B6—Nevirapine—acquired immunodeficiency syndrome	0.0479	0.0517	CbGbCtD
Cinnarizine—CYP2B6—Amprenavir—acquired immunodeficiency syndrome	0.0433	0.0467	CbGbCtD
Cinnarizine—CYP2B6—Nelfinavir—acquired immunodeficiency syndrome	0.0363	0.0392	CbGbCtD
Cinnarizine—CYP2B6—Ritonavir—acquired immunodeficiency syndrome	0.0328	0.0354	CbGbCtD
Cinnarizine—CYP1A2—Efavirenz—acquired immunodeficiency syndrome	0.0299	0.0322	CbGbCtD
Cinnarizine—CYP1A2—Lopinavir—acquired immunodeficiency syndrome	0.0281	0.0303	CbGbCtD
Cinnarizine—CYP1A2—Nevirapine—acquired immunodeficiency syndrome	0.0281	0.0303	CbGbCtD
Cinnarizine—CYP2C9—Efavirenz—acquired immunodeficiency syndrome	0.0269	0.029	CbGbCtD
Cinnarizine—CYP1A2—Delavirdine—acquired immunodeficiency syndrome	0.0254	0.0274	CbGbCtD
Cinnarizine—CYP2C9—Nevirapine—acquired immunodeficiency syndrome	0.0253	0.0273	CbGbCtD
Cinnarizine—CYP2C9—Lopinavir—acquired immunodeficiency syndrome	0.0253	0.0273	CbGbCtD
Cinnarizine—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.0246	0.0266	CbGbCtD
Cinnarizine—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0231	0.025	CbGbCtD
Cinnarizine—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0231	0.025	CbGbCtD
Cinnarizine—CYP2C9—Delavirdine—acquired immunodeficiency syndrome	0.0229	0.0247	CbGbCtD
Cinnarizine—CYP2C9—Amprenavir—acquired immunodeficiency syndrome	0.0229	0.0247	CbGbCtD
Cinnarizine—CYP1A2—Nelfinavir—acquired immunodeficiency syndrome	0.0213	0.023	CbGbCtD
Cinnarizine—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.0209	0.0226	CbGbCtD
Cinnarizine—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.0209	0.0226	CbGbCtD
Cinnarizine—CYP2C9—Indinavir—acquired immunodeficiency syndrome	0.0197	0.0213	CbGbCtD
Cinnarizine—CYP1A2—Ritonavir—acquired immunodeficiency syndrome	0.0192	0.0208	CbGbCtD
Cinnarizine—CYP2C9—Nelfinavir—acquired immunodeficiency syndrome	0.0192	0.0207	CbGbCtD
Cinnarizine—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.0181	0.0195	CbGbCtD
Cinnarizine—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.0175	0.0189	CbGbCtD
Cinnarizine—CYP2C9—Saquinavir—acquired immunodeficiency syndrome	0.0173	0.0187	CbGbCtD
Cinnarizine—CYP2C9—Ritonavir—acquired immunodeficiency syndrome	0.0173	0.0187	CbGbCtD
Cinnarizine—CYP2C9—Zidovudine—acquired immunodeficiency syndrome	0.0166	0.0179	CbGbCtD
Cinnarizine—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.0158	0.0171	CbGbCtD
Cinnarizine—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.0158	0.0171	CbGbCtD
Cinnarizine—CACNA1F—retina—acquired immunodeficiency syndrome	0.0055	0.0896	CbGeAlD
Cinnarizine—HRH4—blood—acquired immunodeficiency syndrome	0.00301	0.0491	CbGeAlD
Cinnarizine—HRH4—bone marrow—acquired immunodeficiency syndrome	0.00291	0.0475	CbGeAlD
Cinnarizine—DRD2—nerve—acquired immunodeficiency syndrome	0.00219	0.0357	CbGeAlD
Cinnarizine—CACNA1G—digestive system—acquired immunodeficiency syndrome	0.00211	0.0345	CbGeAlD
Cinnarizine—CACNA1I—brain—acquired immunodeficiency syndrome	0.00182	0.0297	CbGeAlD
Cinnarizine—CACNA1I—lymph node—acquired immunodeficiency syndrome	0.00176	0.0287	CbGeAlD
Cinnarizine—CACNA1G—nervous system—acquired immunodeficiency syndrome	0.00164	0.0267	CbGeAlD
Cinnarizine—CACNA1G—central nervous system—acquired immunodeficiency syndrome	0.00157	0.0257	CbGeAlD
Cinnarizine—CYP1A2—blood plasma—acquired immunodeficiency syndrome	0.0014	0.0228	CbGeAlD
Cinnarizine—CYP2B6—blood plasma—acquired immunodeficiency syndrome	0.00134	0.0219	CbGeAlD
Cinnarizine—CYP2C9—blood plasma—acquired immunodeficiency syndrome	0.00133	0.0216	CbGeAlD
Cinnarizine—CACNA1G—brain—acquired immunodeficiency syndrome	0.00125	0.0204	CbGeAlD
Cinnarizine—CACNA1H—nervous system—acquired immunodeficiency syndrome	0.00107	0.0174	CbGeAlD
Cinnarizine—CACNA1C—digestive system—acquired immunodeficiency syndrome	0.00105	0.0172	CbGeAlD
Cinnarizine—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.000996	0.0162	CbGeAlD
Cinnarizine—CACNA1D—lung—acquired immunodeficiency syndrome	0.000954	0.0156	CbGeAlD
Cinnarizine—CACNA1C—vagina—acquired immunodeficiency syndrome	0.000931	0.0152	CbGeAlD
Cinnarizine—DRD2—retina—acquired immunodeficiency syndrome	0.000908	0.0148	CbGeAlD
Cinnarizine—CYP2A6—vagina—acquired immunodeficiency syndrome	0.000904	0.0147	CbGeAlD
Cinnarizine—CACNA1D—nervous system—acquired immunodeficiency syndrome	0.000883	0.0144	CbGeAlD
Cinnarizine—CACNA1C—lung—acquired immunodeficiency syndrome	0.00088	0.0144	CbGeAlD
Cinnarizine—CYP2A6—lung—acquired immunodeficiency syndrome	0.000855	0.0139	CbGeAlD
Cinnarizine—CACNA1D—central nervous system—acquired immunodeficiency syndrome	0.00085	0.0139	CbGeAlD
Cinnarizine—CACNA1H—brain—acquired immunodeficiency syndrome	0.000818	0.0133	CbGeAlD
Cinnarizine—CACNA1C—nervous system—acquired immunodeficiency syndrome	0.000815	0.0133	CbGeAlD
Cinnarizine—CACNA1H—lymph node—acquired immunodeficiency syndrome	0.00079	0.0129	CbGeAlD
Cinnarizine—CACNA1C—central nervous system—acquired immunodeficiency syndrome	0.000785	0.0128	CbGeAlD
Cinnarizine—CACNA1D—brain—acquired immunodeficiency syndrome	0.000675	0.011	CbGeAlD
Cinnarizine—CYP1A1—skin of body—acquired immunodeficiency syndrome	0.000663	0.0108	CbGeAlD
Cinnarizine—CACNA1D—lymph node—acquired immunodeficiency syndrome	0.000652	0.0106	CbGeAlD
Cinnarizine—CYP2B6—skin of body—acquired immunodeficiency syndrome	0.000644	0.0105	CbGeAlD
Cinnarizine—CACNA1C—brain—acquired immunodeficiency syndrome	0.000623	0.0102	CbGeAlD
Cinnarizine—CYP2A6—brain—acquired immunodeficiency syndrome	0.000605	0.00987	CbGeAlD
Cinnarizine—CACNA1C—lymph node—acquired immunodeficiency syndrome	0.000602	0.00982	CbGeAlD
Cinnarizine—CYP1A2—digestive system—acquired immunodeficiency syndrome	0.000538	0.00877	CbGeAlD
Cinnarizine—DRD2—lung—acquired immunodeficiency syndrome	0.000532	0.00868	CbGeAlD
Cinnarizine—CYP1A1—digestive system—acquired immunodeficiency syndrome	0.00053	0.00865	CbGeAlD
Cinnarizine—CYP2B6—lymphoid tissue—acquired immunodeficiency syndrome	0.000522	0.00851	CbGeAlD
Cinnarizine—CYP2B6—digestive system—acquired immunodeficiency syndrome	0.000515	0.00841	CbGeAlD
Cinnarizine—CYP1A2—blood—acquired immunodeficiency syndrome	0.000512	0.00835	CbGeAlD
Cinnarizine—CYP2C9—digestive system—acquired immunodeficiency syndrome	0.00051	0.00832	CbGeAlD
Cinnarizine—CYP1A1—blood—acquired immunodeficiency syndrome	0.000505	0.00824	CbGeAlD
Cinnarizine—HRH1—digestive system—acquired immunodeficiency syndrome	0.000503	0.00821	CbGeAlD
Cinnarizine—DRD2—nervous system—acquired immunodeficiency syndrome	0.000493	0.00804	CbGeAlD
Cinnarizine—CYP2B6—blood—acquired immunodeficiency syndrome	0.000491	0.00801	CbGeAlD
Cinnarizine—CYP2C9—blood—acquired immunodeficiency syndrome	0.000486	0.00793	CbGeAlD
Cinnarizine—DRD2—central nervous system—acquired immunodeficiency syndrome	0.000475	0.00774	CbGeAlD
Cinnarizine—CYP1A1—vagina—acquired immunodeficiency syndrome	0.000468	0.00764	CbGeAlD
Cinnarizine—CYP2B6—vagina—acquired immunodeficiency syndrome	0.000455	0.00742	CbGeAlD
Cinnarizine—CYP1A2—lung—acquired immunodeficiency syndrome	0.000449	0.00732	CbGeAlD
Cinnarizine—HRH1—vagina—acquired immunodeficiency syndrome	0.000445	0.00725	CbGeAlD
Cinnarizine—CYP1A1—lung—acquired immunodeficiency syndrome	0.000443	0.00722	CbGeAlD
Cinnarizine—CYP2B6—lung—acquired immunodeficiency syndrome	0.00043	0.00702	CbGeAlD
Cinnarizine—HRH1—lung—acquired immunodeficiency syndrome	0.00042	0.00686	CbGeAlD
Cinnarizine—CYP1A1—nervous system—acquired immunodeficiency syndrome	0.00041	0.00669	CbGeAlD
Cinnarizine—CYP2B6—nervous system—acquired immunodeficiency syndrome	0.000399	0.0065	CbGeAlD
Cinnarizine—CYP1A1—central nervous system—acquired immunodeficiency syndrome	0.000395	0.00644	CbGeAlD
Cinnarizine—HRH1—nervous system—acquired immunodeficiency syndrome	0.000389	0.00635	CbGeAlD
Cinnarizine—CYP2B6—central nervous system—acquired immunodeficiency syndrome	0.000384	0.00626	CbGeAlD
Cinnarizine—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.000383	0.00625	CbGeAlD
Cinnarizine—DRD2—brain—acquired immunodeficiency syndrome	0.000377	0.00615	CbGeAlD
Cinnarizine—HRH1—central nervous system—acquired immunodeficiency syndrome	0.000375	0.00611	CbGeAlD
Cinnarizine—CYP2D6—blood—acquired immunodeficiency syndrome	0.000365	0.00595	CbGeAlD
Cinnarizine—CYP1A1—brain—acquired immunodeficiency syndrome	0.000314	0.00511	CbGeAlD
Cinnarizine—CYP2B6—brain—acquired immunodeficiency syndrome	0.000305	0.00497	CbGeAlD
Cinnarizine—CYP1A1—lymph node—acquired immunodeficiency syndrome	0.000303	0.00494	CbGeAlD
Cinnarizine—HRH1—brain—acquired immunodeficiency syndrome	0.000298	0.00485	CbGeAlD
Cinnarizine—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000296	0.00483	CbGeAlD
Cinnarizine—HRH1—lymph node—acquired immunodeficiency syndrome	0.000288	0.00469	CbGeAlD
Cinnarizine—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.000285	0.00465	CbGeAlD
Cinnarizine—HRH4—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000263	0.0211	CbGpPWpGaD
Cinnarizine—CYP2D6—brain—acquired immunodeficiency syndrome	0.000226	0.00369	CbGeAlD
Cinnarizine—CACNA1I—Axon guidance—ACTG1—acquired immunodeficiency syndrome	0.000222	0.0179	CbGpPWpGaD
Cinnarizine—HRH4—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.0002	0.0161	CbGpPWpGaD
Cinnarizine—DRD2—Circadian rythm related genes—CARTPT—acquired immunodeficiency syndrome	0.000191	0.0154	CbGpPWpGaD
Cinnarizine—CACNA1F—Alzheimers Disease—TNF—acquired immunodeficiency syndrome	0.000181	0.0146	CbGpPWpGaD
Cinnarizine—CACNA1G—Axon guidance—ACTG1—acquired immunodeficiency syndrome	0.000164	0.0132	CbGpPWpGaD
Cinnarizine—HRH4—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000159	0.0128	CbGpPWpGaD
Cinnarizine—CACNA1H—Axon guidance—ACTG1—acquired immunodeficiency syndrome	0.000159	0.0128	CbGpPWpGaD
Cinnarizine—CACNA1I—Developmental Biology—ACTG1—acquired immunodeficiency syndrome	0.000159	0.0128	CbGpPWpGaD
Cinnarizine—HRH4—GPCRs, Other—CCR5—acquired immunodeficiency syndrome	0.000154	0.0124	CbGpPWpGaD
Cinnarizine—HRH4—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000144	0.0116	CbGpPWpGaD
Cinnarizine—CACNA1S—Axon guidance—ACTG1—acquired immunodeficiency syndrome	0.000135	0.0108	CbGpPWpGaD
Cinnarizine—HRH4—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000121	0.00975	CbGpPWpGaD
Cinnarizine—CACNA1G—Developmental Biology—ACTG1—acquired immunodeficiency syndrome	0.000117	0.00942	CbGpPWpGaD
Cinnarizine—CACNA1H—Developmental Biology—ACTG1—acquired immunodeficiency syndrome	0.000113	0.00912	CbGpPWpGaD
Cinnarizine—HRH4—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000112	0.009	CbGpPWpGaD
Cinnarizine—HRH4—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.00011	0.00882	CbGpPWpGaD
Cinnarizine—CACNA1D—Axon guidance—ACTG1—acquired immunodeficiency syndrome	0.000109	0.0088	CbGpPWpGaD
Cinnarizine—CACNA1I—NCAM signaling for neurite out-growth—IL6—acquired immunodeficiency syndrome	0.000109	0.0088	CbGpPWpGaD
Cinnarizine—HRH4—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000105	0.00846	CbGpPWpGaD
Cinnarizine—HRH4—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000105	0.00846	CbGpPWpGaD
Cinnarizine—CACNA1H—Corticotropin-releasing hormone—IL2—acquired immunodeficiency syndrome	0.000104	0.00839	CbGpPWpGaD
Cinnarizine—HRH4—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000103	0.00826	CbGpPWpGaD
Cinnarizine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000102	0.00817	CbGpPWpGaD
Cinnarizine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	9.97e-05	0.00802	CbGpPWpGaD
Cinnarizine—HRH4—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	9.83e-05	0.00791	CbGpPWpGaD
Cinnarizine—CACNA1S—Developmental Biology—ACTG1—acquired immunodeficiency syndrome	9.62e-05	0.00774	CbGpPWpGaD
Cinnarizine—CACNA1C—Axon guidance—ACTG1—acquired immunodeficiency syndrome	9.61e-05	0.00774	CbGpPWpGaD
Cinnarizine—HRH1—IL-4 Signaling Pathway—IL4—acquired immunodeficiency syndrome	9.54e-05	0.00768	CbGpPWpGaD
Cinnarizine—HRH4—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	8.89e-05	0.00715	CbGpPWpGaD
Cinnarizine—HRH4—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	8.36e-05	0.00673	CbGpPWpGaD
Cinnarizine—HRH4—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	8.36e-05	0.00673	CbGpPWpGaD
Cinnarizine—CACNA1G—NCAM signaling for neurite out-growth—IL6—acquired immunodeficiency syndrome	8.06e-05	0.00649	CbGpPWpGaD
Cinnarizine—HRH4—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	8e-05	0.00644	CbGpPWpGaD
Cinnarizine—CACNA1H—NCAM signaling for neurite out-growth—IL6—acquired immunodeficiency syndrome	7.81e-05	0.00628	CbGpPWpGaD
Cinnarizine—CACNA1D—Developmental Biology—ACTG1—acquired immunodeficiency syndrome	7.81e-05	0.00628	CbGpPWpGaD
Cinnarizine—DRD2—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	7.73e-05	0.00622	CbGpPWpGaD
Cinnarizine—HRH1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	7.59e-05	0.00611	CbGpPWpGaD
Cinnarizine—HRH4—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	7.49e-05	0.00602	CbGpPWpGaD
Cinnarizine—CACNA1S—Alzheimers Disease—TNF—acquired immunodeficiency syndrome	7.28e-05	0.00586	CbGpPWpGaD
Cinnarizine—HRH4—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	7.21e-05	0.0058	CbGpPWpGaD
Cinnarizine—CACNA1C—Developmental Biology—ACTG1—acquired immunodeficiency syndrome	6.86e-05	0.00552	CbGpPWpGaD
Cinnarizine—HRH4—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	6.77e-05	0.00545	CbGpPWpGaD
Cinnarizine—CACNA1S—NCAM signaling for neurite out-growth—IL6—acquired immunodeficiency syndrome	6.63e-05	0.00533	CbGpPWpGaD
Cinnarizine—HRH4—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	6.37e-05	0.00512	CbGpPWpGaD
Cinnarizine—HRH4—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	6.37e-05	0.00512	CbGpPWpGaD
Cinnarizine—HRH4—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	6.36e-05	0.00512	CbGpPWpGaD
Cinnarizine—HRH4—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	6.22e-05	0.005	CbGpPWpGaD
Cinnarizine—DRD2—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	6.15e-05	0.00495	CbGpPWpGaD
Cinnarizine—HRH4—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	6.06e-05	0.00488	CbGpPWpGaD
Cinnarizine—HRH1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	6.04e-05	0.00486	CbGpPWpGaD
Cinnarizine—CACNA1D—Alzheimers Disease—TNF—acquired immunodeficiency syndrome	5.91e-05	0.00476	CbGpPWpGaD
Cinnarizine—HRH4—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	5.73e-05	0.00461	CbGpPWpGaD
Cinnarizine—HRH4—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	5.62e-05	0.00453	CbGpPWpGaD
Cinnarizine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	5.56e-05	0.00448	CbGpPWpGaD
Cinnarizine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	5.46e-05	0.00439	CbGpPWpGaD
Cinnarizine—CACNA1D—NCAM signaling for neurite out-growth—IL6—acquired immunodeficiency syndrome	5.38e-05	0.00433	CbGpPWpGaD
Cinnarizine—CACNA1D—Metabolism—TAT—acquired immunodeficiency syndrome	5.27e-05	0.00424	CbGpPWpGaD
Cinnarizine—CACNA1C—Alzheimers Disease—TNF—acquired immunodeficiency syndrome	5.2e-05	0.00418	CbGpPWpGaD
Cinnarizine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—acquired immunodeficiency syndrome	5.17e-05	0.00416	CbGpPWpGaD
Cinnarizine—HRH4—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	4.84e-05	0.0039	CbGpPWpGaD
Cinnarizine—CACNA1C—NCAM signaling for neurite out-growth—IL6—acquired immunodeficiency syndrome	4.73e-05	0.0038	CbGpPWpGaD
Cinnarizine—DRD2—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	4.68e-05	0.00377	CbGpPWpGaD
Cinnarizine—CACNA1C—Metabolism—TAT—acquired immunodeficiency syndrome	4.63e-05	0.00373	CbGpPWpGaD
Cinnarizine—HRH1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	4.6e-05	0.0037	CbGpPWpGaD
Cinnarizine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	4.6e-05	0.0037	CbGpPWpGaD
Cinnarizine—CACNA1D—Metabolism—AGPS—acquired immunodeficiency syndrome	4.48e-05	0.00361	CbGpPWpGaD
Cinnarizine—HRH4—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	4.36e-05	0.00351	CbGpPWpGaD
Cinnarizine—DRD2—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	4.32e-05	0.00348	CbGpPWpGaD
Cinnarizine—DRD2—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	4.24e-05	0.00341	CbGpPWpGaD
Cinnarizine—HRH1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	4.16e-05	0.00335	CbGpPWpGaD
Cinnarizine—DRD2—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	4.06e-05	0.00327	CbGpPWpGaD
Cinnarizine—DRD2—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	4.06e-05	0.00327	CbGpPWpGaD
Cinnarizine—DRD2—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	4.01e-05	0.00323	CbGpPWpGaD
Cinnarizine—DRD2—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	3.97e-05	0.00319	CbGpPWpGaD
Cinnarizine—HRH1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	3.94e-05	0.00317	CbGpPWpGaD
Cinnarizine—CACNA1C—Metabolism—AGPS—acquired immunodeficiency syndrome	3.94e-05	0.00317	CbGpPWpGaD
Cinnarizine—HRH1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	3.9e-05	0.00313	CbGpPWpGaD
Cinnarizine—HRH4—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	3.84e-05	0.00309	CbGpPWpGaD
Cinnarizine—HRH4—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	3.83e-05	0.00308	CbGpPWpGaD
Cinnarizine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	3.8e-05	0.00306	CbGpPWpGaD
Cinnarizine—DRD2—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	3.77e-05	0.00303	CbGpPWpGaD
Cinnarizine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	3.73e-05	0.003	CbGpPWpGaD
Cinnarizine—HRH1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	3.7e-05	0.00298	CbGpPWpGaD
Cinnarizine—CYP1A1—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	3.7e-05	0.00297	CbGpPWpGaD
Cinnarizine—HRH4—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	3.67e-05	0.00296	CbGpPWpGaD
Cinnarizine—HRH4—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	3.67e-05	0.00296	CbGpPWpGaD
Cinnarizine—HRH4—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	3.6e-05	0.00289	CbGpPWpGaD
Cinnarizine—HRH4—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	3.6e-05	0.00289	CbGpPWpGaD
Cinnarizine—HRH4—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.48e-05	0.0028	CbGpPWpGaD
Cinnarizine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	3.44e-05	0.00277	CbGpPWpGaD
Cinnarizine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	3.37e-05	0.00272	CbGpPWpGaD
Cinnarizine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	3.35e-05	0.0027	CbGpPWpGaD
Cinnarizine—CYP1A1—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	3.35e-05	0.0027	CbGpPWpGaD
Cinnarizine—HRH4—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.32e-05	0.00267	CbGpPWpGaD
Cinnarizine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—acquired immunodeficiency syndrome	3.3e-05	0.00265	CbGpPWpGaD
Cinnarizine—HRH4—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.27e-05	0.00263	CbGpPWpGaD
Cinnarizine—HRH4—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.27e-05	0.00263	CbGpPWpGaD
Cinnarizine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	3.23e-05	0.0026	CbGpPWpGaD
Cinnarizine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	3.23e-05	0.0026	CbGpPWpGaD
Cinnarizine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	3.17e-05	0.00255	CbGpPWpGaD
Cinnarizine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	3.17e-05	0.00255	CbGpPWpGaD
Cinnarizine—CACNA1I—Axon guidance—IL6—acquired immunodeficiency syndrome	3.14e-05	0.00252	CbGpPWpGaD
Cinnarizine—DRD2—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	3.09e-05	0.00249	CbGpPWpGaD
Cinnarizine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—acquired immunodeficiency syndrome	2.93e-05	0.00236	CbGpPWpGaD
Cinnarizine—DRD2—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	2.89e-05	0.00233	CbGpPWpGaD
Cinnarizine—HRH1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	2.84e-05	0.00229	CbGpPWpGaD
Cinnarizine—DRD2—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	2.79e-05	0.00224	CbGpPWpGaD
Cinnarizine—CACNA1I—Developmental Biology—TNF—acquired immunodeficiency syndrome	2.77e-05	0.00223	CbGpPWpGaD
Cinnarizine—CYP2C9—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	2.76e-05	0.00222	CbGpPWpGaD
Cinnarizine—HRH4—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	2.74e-05	0.0022	CbGpPWpGaD
Cinnarizine—HRH4—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	2.7e-05	0.00217	CbGpPWpGaD
Cinnarizine—DRD2—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	2.62e-05	0.00211	CbGpPWpGaD
Cinnarizine—CYP2A6—Metabolism—TAT—acquired immunodeficiency syndrome	2.6e-05	0.00209	CbGpPWpGaD
Cinnarizine—DRD2—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	2.58e-05	0.00208	CbGpPWpGaD
Cinnarizine—HRH1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	2.57e-05	0.00207	CbGpPWpGaD
Cinnarizine—HRH1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	2.54e-05	0.00204	CbGpPWpGaD
Cinnarizine—HRH4—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.49e-05	0.002	CbGpPWpGaD
Cinnarizine—HRH4—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.47e-05	0.00198	CbGpPWpGaD
Cinnarizine—DRD2—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	2.46e-05	0.00198	CbGpPWpGaD
Cinnarizine—DRD2—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	2.46e-05	0.00198	CbGpPWpGaD
Cinnarizine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	2.46e-05	0.00198	CbGpPWpGaD
Cinnarizine—HRH4—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.45e-05	0.00197	CbGpPWpGaD
Cinnarizine—HRH1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	2.42e-05	0.00194	CbGpPWpGaD
Cinnarizine—HRH1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	2.42e-05	0.00194	CbGpPWpGaD
Cinnarizine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	2.41e-05	0.00194	CbGpPWpGaD
Cinnarizine—DRD2—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	2.4e-05	0.00193	CbGpPWpGaD
Cinnarizine—HRH1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	2.36e-05	0.0019	CbGpPWpGaD
Cinnarizine—CYP1A2—Metabolism of lipids and lipoproteins—AGPS—acquired immunodeficiency syndrome	2.36e-05	0.0019	CbGpPWpGaD
Cinnarizine—DRD2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	2.34e-05	0.00189	CbGpPWpGaD
Cinnarizine—CACNA1G—Axon guidance—IL6—acquired immunodeficiency syndrome	2.31e-05	0.00186	CbGpPWpGaD
Cinnarizine—HRH1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	2.3e-05	0.00185	CbGpPWpGaD
Cinnarizine—HRH4—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.27e-05	0.00183	CbGpPWpGaD
Cinnarizine—CACNA1H—Axon guidance—IL6—acquired immunodeficiency syndrome	2.24e-05	0.0018	CbGpPWpGaD
Cinnarizine—HRH4—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.24e-05	0.0018	CbGpPWpGaD
Cinnarizine—CACNA1I—Developmental Biology—IL6—acquired immunodeficiency syndrome	2.24e-05	0.0018	CbGpPWpGaD
Cinnarizine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	2.21e-05	0.00178	CbGpPWpGaD
Cinnarizine—CYP2A6—Metabolism—AGPS—acquired immunodeficiency syndrome	2.21e-05	0.00178	CbGpPWpGaD
Cinnarizine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	2.17e-05	0.00175	CbGpPWpGaD
Cinnarizine—DRD2—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	2.17e-05	0.00175	CbGpPWpGaD
Cinnarizine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—acquired immunodeficiency syndrome	2.14e-05	0.00172	CbGpPWpGaD
Cinnarizine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—acquired immunodeficiency syndrome	2.14e-05	0.00172	CbGpPWpGaD
Cinnarizine—HRH1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	2.13e-05	0.00172	CbGpPWpGaD
Cinnarizine—CYP2B6—Metabolism—TAT—acquired immunodeficiency syndrome	2.1e-05	0.00169	CbGpPWpGaD
Cinnarizine—HRH4—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.05e-05	0.00165	CbGpPWpGaD
Cinnarizine—CACNA1G—Developmental Biology—TNF—acquired immunodeficiency syndrome	2.05e-05	0.00165	CbGpPWpGaD
Cinnarizine—CACNA1H—Developmental Biology—TNF—acquired immunodeficiency syndrome	1.98e-05	0.00159	CbGpPWpGaD
Cinnarizine—CYP1A1—Metabolism—TAT—acquired immunodeficiency syndrome	1.94e-05	0.00156	CbGpPWpGaD
Cinnarizine—HRH4—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.93e-05	0.00155	CbGpPWpGaD
Cinnarizine—HRH4—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.93e-05	0.00155	CbGpPWpGaD
Cinnarizine—CACNA1S—Axon guidance—IL6—acquired immunodeficiency syndrome	1.9e-05	0.00153	CbGpPWpGaD
Cinnarizine—DRD2—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	1.87e-05	0.00151	CbGpPWpGaD
Cinnarizine—HRH1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	1.84e-05	0.00148	CbGpPWpGaD
Cinnarizine—CYP2B6—Metabolism—AGPS—acquired immunodeficiency syndrome	1.78e-05	0.00143	CbGpPWpGaD
Cinnarizine—DRD2—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	1.69e-05	0.00136	CbGpPWpGaD
Cinnarizine—CACNA1S—Developmental Biology—TNF—acquired immunodeficiency syndrome	1.68e-05	0.00135	CbGpPWpGaD
Cinnarizine—HRH1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	1.66e-05	0.00133	CbGpPWpGaD
Cinnarizine—CACNA1G—Developmental Biology—IL6—acquired immunodeficiency syndrome	1.65e-05	0.00133	CbGpPWpGaD
Cinnarizine—CYP1A1—Metabolism—AGPS—acquired immunodeficiency syndrome	1.65e-05	0.00132	CbGpPWpGaD
Cinnarizine—CACNA1H—Developmental Biology—IL6—acquired immunodeficiency syndrome	1.6e-05	0.00129	CbGpPWpGaD
Cinnarizine—CACNA1D—Axon guidance—IL6—acquired immunodeficiency syndrome	1.54e-05	0.00124	CbGpPWpGaD
Cinnarizine—DRD2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.49e-05	0.00119	CbGpPWpGaD
Cinnarizine—DRD2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.48e-05	0.00119	CbGpPWpGaD
Cinnarizine—HRH4—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.47e-05	0.00118	CbGpPWpGaD
Cinnarizine—HRH1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	1.46e-05	0.00117	CbGpPWpGaD
Cinnarizine—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	1.46e-05	0.00117	CbGpPWpGaD
Cinnarizine—HRH1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	1.45e-05	0.00117	CbGpPWpGaD
Cinnarizine—HRH4—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.45e-05	0.00116	CbGpPWpGaD
Cinnarizine—CYP2C9—Metabolism—TAT—acquired immunodeficiency syndrome	1.44e-05	0.00116	CbGpPWpGaD
Cinnarizine—HRH4—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.42e-05	0.00115	CbGpPWpGaD
Cinnarizine—DRD2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.42e-05	0.00114	CbGpPWpGaD
Cinnarizine—DRD2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.42e-05	0.00114	CbGpPWpGaD
Cinnarizine—HRH1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	1.39e-05	0.00112	CbGpPWpGaD
Cinnarizine—HRH1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	1.39e-05	0.00112	CbGpPWpGaD
Cinnarizine—DRD2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.39e-05	0.00112	CbGpPWpGaD
Cinnarizine—DRD2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.39e-05	0.00112	CbGpPWpGaD
Cinnarizine—HRH1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	1.37e-05	0.0011	CbGpPWpGaD
Cinnarizine—HRH1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	1.37e-05	0.0011	CbGpPWpGaD
Cinnarizine—CACNA1D—Developmental Biology—TNF—acquired immunodeficiency syndrome	1.36e-05	0.0011	CbGpPWpGaD
Cinnarizine—CACNA1S—Developmental Biology—IL6—acquired immunodeficiency syndrome	1.36e-05	0.00109	CbGpPWpGaD
Cinnarizine—CACNA1C—Axon guidance—IL6—acquired immunodeficiency syndrome	1.36e-05	0.00109	CbGpPWpGaD
Cinnarizine—DRD2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.34e-05	0.00108	CbGpPWpGaD
Cinnarizine—HRH4—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.32e-05	0.00106	CbGpPWpGaD
Cinnarizine—HRH1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	1.32e-05	0.00106	CbGpPWpGaD
Cinnarizine—HRH4—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.29e-05	0.00104	CbGpPWpGaD
Cinnarizine—DRD2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.28e-05	0.00103	CbGpPWpGaD
Cinnarizine—DRD2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.26e-05	0.00102	CbGpPWpGaD
Cinnarizine—DRD2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.26e-05	0.00102	CbGpPWpGaD
Cinnarizine—HRH1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	1.26e-05	0.00101	CbGpPWpGaD
Cinnarizine—HRH1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	1.24e-05	0.000998	CbGpPWpGaD
Cinnarizine—HRH1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	1.24e-05	0.000998	CbGpPWpGaD
Cinnarizine—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	1.24e-05	0.000997	CbGpPWpGaD
Cinnarizine—CYP1A2—Metabolism—TAT—acquired immunodeficiency syndrome	1.23e-05	0.000993	CbGpPWpGaD
Cinnarizine—CYP2C9—Metabolism—AGPS—acquired immunodeficiency syndrome	1.23e-05	0.000988	CbGpPWpGaD
Cinnarizine—CACNA1C—Developmental Biology—TNF—acquired immunodeficiency syndrome	1.2e-05	0.000965	CbGpPWpGaD
Cinnarizine—CACNA1D—Developmental Biology—IL6—acquired immunodeficiency syndrome	1.1e-05	0.000886	CbGpPWpGaD
Cinnarizine—DRD2—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	1.07e-05	0.000863	CbGpPWpGaD
Cinnarizine—DRD2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.06e-05	0.000851	CbGpPWpGaD
Cinnarizine—CYP1A2—Metabolism—AGPS—acquired immunodeficiency syndrome	1.05e-05	0.000845	CbGpPWpGaD
Cinnarizine—DRD2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.04e-05	0.000838	CbGpPWpGaD
Cinnarizine—HRH1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	1.04e-05	0.000836	CbGpPWpGaD
Cinnarizine—HRH1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	1.02e-05	0.000823	CbGpPWpGaD
Cinnarizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	9.97e-06	0.000802	CbGpPWpGaD
Cinnarizine—CACNA1C—Developmental Biology—IL6—acquired immunodeficiency syndrome	9.68e-06	0.000779	CbGpPWpGaD
Cinnarizine—DRD2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	9.61e-06	0.000773	CbGpPWpGaD
Cinnarizine—DRD2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	9.53e-06	0.000767	CbGpPWpGaD
Cinnarizine—DRD2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	9.46e-06	0.000761	CbGpPWpGaD
Cinnarizine—HRH1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	9.43e-06	0.000759	CbGpPWpGaD
Cinnarizine—HRH1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	9.36e-06	0.000753	CbGpPWpGaD
Cinnarizine—HRH1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	9.29e-06	0.000748	CbGpPWpGaD
Cinnarizine—CACNA1D—Metabolism—ALB—acquired immunodeficiency syndrome	9.19e-06	0.000739	CbGpPWpGaD
Cinnarizine—DRD2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	8.77e-06	0.000706	CbGpPWpGaD
Cinnarizine—DRD2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	8.65e-06	0.000696	CbGpPWpGaD
Cinnarizine—HRH1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	8.61e-06	0.000693	CbGpPWpGaD
Cinnarizine—HRH1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	8.5e-06	0.000684	CbGpPWpGaD
Cinnarizine—CACNA1C—Metabolism—ALB—acquired immunodeficiency syndrome	8.07e-06	0.00065	CbGpPWpGaD
Cinnarizine—DRD2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	7.93e-06	0.000638	CbGpPWpGaD
Cinnarizine—HRH1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	7.79e-06	0.000627	CbGpPWpGaD
Cinnarizine—HRH4—Signaling Pathways—IL2—acquired immunodeficiency syndrome	7.64e-06	0.000615	CbGpPWpGaD
Cinnarizine—HRH4—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	7.6e-06	0.000612	CbGpPWpGaD
Cinnarizine—CYP1A1—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	7.58e-06	0.00061	CbGpPWpGaD
Cinnarizine—DRD2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	7.46e-06	0.0006	CbGpPWpGaD
Cinnarizine—DRD2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	7.46e-06	0.0006	CbGpPWpGaD
Cinnarizine—HRH1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	7.32e-06	0.000589	CbGpPWpGaD
Cinnarizine—HRH1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	7.32e-06	0.000589	CbGpPWpGaD
Cinnarizine—DRD2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	5.68e-06	0.000457	CbGpPWpGaD
Cinnarizine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	5.66e-06	0.000455	CbGpPWpGaD
Cinnarizine—DRD2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.59e-06	0.00045	CbGpPWpGaD
Cinnarizine—HRH1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	5.57e-06	0.000448	CbGpPWpGaD
Cinnarizine—DRD2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	5.51e-06	0.000443	CbGpPWpGaD
Cinnarizine—HRH1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	5.49e-06	0.000442	CbGpPWpGaD
Cinnarizine—HRH1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	5.41e-06	0.000435	CbGpPWpGaD
Cinnarizine—DRD2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.11e-06	0.000411	CbGpPWpGaD
Cinnarizine—HRH1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.02e-06	0.000404	CbGpPWpGaD
Cinnarizine—DRD2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	5e-06	0.000402	CbGpPWpGaD
Cinnarizine—HRH1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	4.91e-06	0.000395	CbGpPWpGaD
Cinnarizine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	4.83e-06	0.000389	CbGpPWpGaD
Cinnarizine—CYP2A6—Metabolism—ALB—acquired immunodeficiency syndrome	4.53e-06	0.000365	CbGpPWpGaD
Cinnarizine—HRH4—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.49e-06	0.000361	CbGpPWpGaD
Cinnarizine—CYP2B6—Metabolism—ALB—acquired immunodeficiency syndrome	3.66e-06	0.000294	CbGpPWpGaD
Cinnarizine—CYP1A1—Metabolism—ALB—acquired immunodeficiency syndrome	3.38e-06	0.000272	CbGpPWpGaD
Cinnarizine—DRD2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.95e-06	0.000238	CbGpPWpGaD
Cinnarizine—DRD2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.94e-06	0.000237	CbGpPWpGaD
Cinnarizine—HRH1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.9e-06	0.000233	CbGpPWpGaD
Cinnarizine—HRH1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.89e-06	0.000232	CbGpPWpGaD
Cinnarizine—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	2.54e-06	0.000204	CbGpPWpGaD
Cinnarizine—CYP2C9—Metabolism—ALB—acquired immunodeficiency syndrome	2.52e-06	0.000203	CbGpPWpGaD
Cinnarizine—CYP1A2—Metabolism—ALB—acquired immunodeficiency syndrome	2.15e-06	0.000173	CbGpPWpGaD
Cinnarizine—DRD2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.74e-06	0.00014	CbGpPWpGaD
Cinnarizine—HRH1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.7e-06	0.000137	CbGpPWpGaD
